The coordinates and structure factor files have been deposited in the Protein Data Bank under the accession code [4BBH](4BBH).

Introduction {#sec1}
============

Diseases resulting from parasitic infections are a global health crisis, responsible for over 700 000 annual deaths and predominantly affecting developing countries.^[@ref1]^ The most serious is malaria, caused by parasites of the genus *Plasmodium*. The vast majority of malaria infections stem from the species *Plasmodium falciparum* (Pf) and *Plasmodium vivax* (Pv). Emerging resistance to current therapies highlights the urgent requirement for new antimalarial medications in the near future.^[@ref2]^

*N*-Myristoyltransferase (NMT) is an enzyme found exclusively in eukaryotes and is responsible for the co- and post-translational attachment of the C~14~ fatty acid myristic acid to the N-terminal glycine of substrate proteins.^[@ref3]^ In malaria, essential proteins such as calcium dependent protein kinase 1^[@ref4]^ and glideosome associated protein 45^[@ref5]^ have been shown to require myristoylation to carry out their biological functions. Furthermore, genetic experiments have shown NMT to be essential in *Plasmodium berghei* in vivo.^[@ref6]^ This evidence strongly suggests that NMT is a highly promising antiparasitic drug target.

Results and Discussion {#sec2}
======================

Our previous work has led to the identification of parasite NMT inhibitors via high throughput screening.^[@ref7],[@ref8]^ As an alternative strategy for hit discovery, NMT has been highlighted as a target for the piggy-back approach.^[@ref9]^ We have used this methodology successfully to produce a series of moderate affinity and selective PfNMT inhibitors adapted from antifungal NMT inhibitors developed initially by Roche (**1**, Table [1](#tbl1){ref-type="other"}).^[@ref10]^ Although **1** displays selectivity over the human NMT orthologues (HsNMT) and moderate enzyme affinity, its relatively large size means that the ligand efficiency (LE) is significantly lower than 0.35, the average LE of high-throughput screening hits.^[@ref11]^ A poor LE limits the potential of a series in hit to lead development, increasing the chances of later stage attrition. We therefore sought to develop this series with the aim of producing more ligand efficient, selective, and novel hit series for PfNMT and PvNMT.

On the basis of the available crystallographic information,^[@ref12]^ it was hypothesized that lead hopping by moving the amine substituent from the 4-position on the benzo\[*b*\]furan scaffold to the 3-position would be tolerated by the enzyme. This modification would allow the exploration of novel chemical space, facilitating the discovery of novel parasitic NMT inhibitors.

Synthesis of the template was achieved by a Williamson ether synthesis followed by Dieckmann condensation, affording **3** in high yield. A Mitsunobu reaction and deprotection resulted in **5**, designed as an analogue of **1** (Scheme [1](#sch1){ref-type="scheme"}). Pleasingly, this shift in substitution pattern resulted in a 10-fold affinity improvement against PvNMT, a 3-fold improvement against PfNMT, and no measurable activity against HsNMT up to 100 μM. Coupled with the loss of one heavy atom, this improved the LE to 0.38 for PvNMT and 0.35 for PfNMT (Table [1](#tbl1){ref-type="other"}).

A range of amines was synthesized to investigate the linker length, basicity, and lipophilicity requirements (see [Supporting Information](#notes-1){ref-type="notes"}). All changes resulted in complete loss of affinity against all three enzymes, reinforcing previous results from a related series that the piperidine substituent is strongly preferred for affinity.^[@ref10]^ For each of these syntheses, the Mitsunobu reaction proceeded with a disappointingly poor yield, typically less than 50%. It was hypothesized that despite the potential for an intramolecular hydrogen bond, the weakly aromatic furan ring^[@ref13]^ resulted in significant tautomerism between **3** and the undesired ketone tautomer **6** (Figure [1](#fig1){ref-type="fig"}). Mitsunobu reactions utilizing the disfavored enol tautomer have been previously reported with reactive electrophiles;^[@ref14]^ however, it is also known that the presence of carbonyls^[@ref15]^ and highly acidic α-carbonyl protons^[@ref16]^ can produce side reactions. Furthermore, the unstable heterocycle may lead to problems with stability and toxicity due to the presence of an (albeit hindered) α,β-unsaturated carbonyl in **5** not stabilized by aromaticity.

![Synthesis of Benzo\[*b*\]furan **1**\
Reagents and conditions: (a) ethyl bromoacetate, K~2~CO~3~, acetone, reflux, 3 h, 96%; (b) *t-*BuOK, THF, rt, 15 min, 94%; (c) 1-Boc-4-piperidinol, diisopropyl azodicarboxylate, PPh~3~, THF, rt, 18 h, 26%; (d) 10% TFA in DCM (v/v), rt, 2 h, 97%.](jm-2012-01474t_0003){#sch1}

![Tautomeric forms of benzo\[*b*\]furan **3**.](jm-2012-01474t_0001){#fig1}

It is known that the aromatic stabilization energy of benzo\[*b*\]thiophenes is far greater than that of benzo\[*b*\]furans^[@ref13]^ and that this results in a higher population of the enol tautomer.^[@ref17]^ It was therefore proposed that the bioisosteric replacement of the benzo\[*b*\]furan core with benzo\[*b*\]thiophene may improve the synthetic efficiency. Furthermore, the benzo\[*b*\]furan scaffold is known to form π-interactions with Tyr334 and Ty211 in PvNMT;^[@ref10]^ therefore, the increased aromatic character of the benzo\[*b*\]thiophene scaffold may result in improved interactions between the scaffold and these residues.

![Synthesis of Benzo\[*b*\]thiophene **9**\
Reagents and conditions: (a) ethyl bromoacetate, *t*-BuOK, THF, rt, 15 min, 88%; (b) 1-Boc-4-piperidinol, diisopropyl azodicarboxylate, PPh~3~, THF, rt, 1.5 h, 97%; (c) 10% TFA in DCM (v/v), rt, 2 h, 82%.](jm-2012-01474t_0004){#sch2}

Replacement of oxygen with sulfur enabled modification of the Williamson ether synthesis/Dieckmann condensation into a one-pot cascade procedure and dramatically improved the yield of the Mitsunobu ether synthesis from 26% to 97% (Scheme [2](#sch2){ref-type="scheme"}).

**9** had 3-fold higher PfNMT affinity than **5**, retained HsNMT selectivity, increased structural diversity in the series, and displayed favorable ligand efficiency (Table [1](#tbl1){ref-type="other"}). In addition, **9** displayed significantly improved antiparasitic activity in vitro compared to **5** (Table [1](#tbl1){ref-type="other"}) and exhibited equal binding affinity to PvNMT and PfNMT. **9** was therefore a highly promising plasmodial NMT inhibitor and was selected for further hit to lead development.

Previous work indicated that replacement of the ethyl ester with a *m*-methoxybenzyl may provide additional affinity (\>100-fold in a related series) via hydrophobic interactions and introduction of a methoxy substituent capable of forming a polar interaction with a serine residue in the active site.^[@ref10]^ A small selection of benzyl esters and amides was synthesized to probe this possibility within this series of inhibitors (Scheme [3](#sch3){ref-type="scheme"}).

Throughout this series, amides displayed consistently lower affinity than esters, and the benzyl substituent resulted in the loss of a great deal of selectivity compared to ethyl ester **9**. Although incorporation of 3-methoxyphenyl (**12b**, Table [1](#tbl1){ref-type="other"}) produced only a modest improvement in PfNMT enzyme affinity (**9** vs **12b,** Table [1](#tbl1){ref-type="other"}), the improvement in PvNMT is far more pronounced. In addition, **12b** is the most potent antiplasmodial compound of this series with an EC~50~ of 2.0 μM.

The results in Table [1](#tbl1){ref-type="other"} indicate that the targeted interactions from the additional aromatic group are not being formed; the benzyl ester **12a** is less potent than **9**, implying suboptimal interactions for this substituent. Nonetheless, **12b** displays excellent PvNMT enzyme affinity and is 10-fold selective over PfNMT. This is in contrast to previous results with a related series, indicating the potential for a novel binding mode of this series compared to the 2,3,4-benzofuran analogues (exemplified by **1**).^[@ref10]^

The strong enzyme affinity of **12b** for PvNMT facilitated determination of the structure of **12b** bound to the active site of PvNMT (Figure [2](#fig2){ref-type="fig"}, PDB accession code [4BBH](4BBH)). As implied by the structure--activity relationship in Table [1](#tbl1){ref-type="other"}, **12b** adopts an overlapping but distinct binding mode to the 2,3,4-benzofuran series (Figure [2](#fig2){ref-type="fig"}C, PDB accession code [4B14](4B14)). The interaction between the basic amine moiety and the α-carboxylate of the C-terminal leucine of the protein appears to dominate (Figure [2](#fig2){ref-type="fig"}A), with both inhibitors aligning to form this interaction (Figure [2](#fig2){ref-type="fig"}C). The chemically similar benzofuran and benzothiophene rings occupy distinct locations within the enzyme pocket (Figure [2](#fig2){ref-type="fig"}C). The altered substitution pattern results in the benzothiophene scaffold being buried deeper within a hydrophobic pocket (Figure [2](#fig2){ref-type="fig"}B), providing a rationalization for the high PvNMT enzyme affinity of **12b**. As a result of the displacement of the scaffold, the methoxyphenyl group of **12b** is unable to reach the pocket occupied by this substituent in the 2,3,4-benzofuran inhibitor (Figure [2](#fig2){ref-type="fig"}C). This results in suboptimal binding of this portion of the molecule, with multiple alternative binding positions visible in the three protein chains present in the asymmetric unit (Figure [2](#fig2){ref-type="fig"}B,C). There is clearly scope for optimizing this substituent, perhaps by extending the linker between the methoxyphenyl group and the scaffold to reach the targeted pocket.

###### Enzyme Affinity, Parasitic LE, and in Vitro Activity for Compounds **1**, **5**, **9**, **12a**,**b**, **14a**,**b**

![](jm-2012-01474t_0006){#fx1}

*K*~i~ values are quoted in place of IC~50~ values as a means of expressing the inhibitor affinity while correcting for differing Michaelis constants between enzymes. Enzyme *K*~i~ values are calculated from the IC~50~ values using the Cheng--Prusoff equation (see [Supporting Information](#notes-1){ref-type="notes"}). IC~50~ values are the mean of two or more determinations. Standard deviation is within 20% of the IC~50~.

LE = \[−log(*K*~i~)\](1.374)/(no. of heavy atoms).

The HsNMT affinities reported in this work refer to HsNMT1; no significant difference in inhibition has been observed between HsNMT1 and HsNMT2 isoforms.

EC~50~ values for *P. falciparum* cultured in vitro. 3D7 is a chloroquine-sensitive strain of *P. falciparum*.

![Synthesis of Benzyl Esters and Amides\
Reagents and conditions (a) LiOH·H~2~O, MeOH, rt, 3 h, 58%; (b) 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydroxybenzotriazole, *N*,*N*-diisopropylethylamine, MeCN, rt, 18 h, 55--66%; (c) benzotriazo-1-yloxytripyrrolidinophosphonium hexafluorophosphate, *N*,*N*-diisopropylethylamine, DCM, rt, 18 h, 66--74%; (d) 10% TFA in DCM (v/v), rt, 2 h, 18--81%.](jm-2012-01474t_0005){#sch3}

The fluctuating selectivity of inhibitors in this series for NMT orthologues is difficult to rationalize based on the crystallographic information; the only residue difference within 5 Å of the active site is the substitution of Tyr334 in PvNMT by Phe334 in PfNMT, with HsNMT and PvNMT displaying a completely homologous active site. The reasons for selectivity are likely to be more subtle, perhaps because of long-range factors modulating stereoelectronic interactions or protein dynamics in the binding site.

The current series contains a potentially biologically labile ester group, and as yet we have no information about the metabolic stability. Further development will focus on compound stability with potency and selectivity to produce a robust lead series for further development.

![X-ray structure of inhibitors bound to PvNMT.^[@ref18]^ (A) A crucial interaction between the enzyme and inhibitor involves the amine of the piperidine moiety of **12b** (purple) and a hydrophilic pocket incorporating the enzyme C-terminal carboxylate (Leu410). (B) In this binding mode the benzo\[*b*\]thiophene scaffold is deeply buried within the binding pocket. Although this portion of the inhibitor is well-defined, the electron density identifies multiple alternative binding positions for the benzyl ester moiety, as shown by thin bonds (see [Supporting Information](#notes-1){ref-type="notes"}). This substituent is clearly suboptimal, suggesting an area of future development for this series. (C) The contrasting binding modes are clearly shown by overlay of the PvNMT complex formed by **12b** (purple) with that formed by a previously discovered 2,3,4-benzofuran inhibitor (green).^[@ref10]^ The novel binding mode explains the difference in SAR between the two series.](jm-2012-01474t_0002){#fig2}

Conclusion {#sec3}
==========

Analysis of structural information indicated the potential for chemical diversity of a Pf/PvNMT inhibitor via a lead-hopping approach. Altering the positions of scaffold substitution and scaffold-hopping based on aromatic stabilization yielded highly selective and ligand efficient **9** that is built around a benzo\[*b*\]thiophene core. Attempts to translate structure--activity relationships developed in a related series yielded **12b**. Compound **12b** is a structurally novel, high affinity PvNMT inhibitor that displays excellent LE and antiplasmodial activity in vitro. The crystal structure of **12b** bound to PvNMT highlighted a novel binding mode for this scaffold.

Experimental Section {#sec4}
====================

Purity of tested compounds was ≥95% unless otherwise specified, as confirmed by LC--MS.

Ethyl 3-Hydroxybenzo\[*b*\]thiophene-2-carboxylate **7** {#sec4.1}
--------------------------------------------------------

To a solution of methyl 2-mercaptobenzoate (1.63 mL, 11.9 mmol) and ethyl bromoacetate (1.32 mL, 11.9 mmol) in dry THF (130 mL) at 0 °C was added potassium *tert*-butoxide (5.14 g, 71.3 mmol) gradually over 2 min. The mixture was stirred and allowed to warm to rt over 15 min, quenched with 2 M HCl solution to pH 2, and diluted with 75 mL of water. **7** was extracted with 3 × 75 mL portions of EtOAc. The organic layers were combined, washed with 75 mL of brine, dried over MgSO~4~, and concentrated under reduced pressure to give product **7** as a yellow solid (2.32 g, 88%). ^1^H NMR (CDCl~3~, δ, ppm) 10.21 (1H, s), 7.94 (1H, d, *J* = 8.0), 7.74 (1H, d, *J* = 8.0), 7.50 (1H, ddd, *J* = 8.0, 7.5, 1.4), 7.44--7.37 (1H, m), 4.43 (2H, q, *J* = 7.1), 1.43 (3H, t, *J* = 7.1).

*tert*-Butyl 4-((2-(Ethoxycarbonyl)benzo\[*b*\]thiophen-3-yl)oxy)piperidine-1-carboxylate **8** {#sec4.2}
-----------------------------------------------------------------------------------------------

To a solution of **7** (2.70 g, 12.2 mmol) in THF (30 mL) were added *tert*-butyl 4-hydroxypiperidine-1-carboxylate (4.89 g, 24.3 mmol) and triphenylphosphine (6.38 g, 24.3 mmol). The mixture was stirred under nitrogen for 20 min and cooled to 0 °C. Diisopropyl azodicarboxylate (4.79 mL, 24.3 mmol) in THF (10 mL) was added dropwise over 5 min. The mixture was warmed to rt and stirred for 1.5 h, then concentrated under reduced pressure and purified by flash chromatography, yielding **8** as a pink oil (4.77 g, 97%). ^1^H NMR (CDCl~3~, δ, ppm) 7.86 (1H, d, *J* = 7.9), 7.74 (1H, d, *J* = 8.0), 7.47 (1H, ddd, *J* = 8.0, 7.8, 0.8), 7.39 (1H, dd, *J* = 7.9, 7.8), 4.79--4.69 (1H, m), 4.38 (2H, q, *J* = 7.2), 4.01--3.86 (2H, m), 3.20--3.07 (2H, m), 2.05--1.95 (2H, m), 1.91--1.79 (2H, m), 1.48 (9H, s), 1.41 (3H, t, *J* = 7.2).

3-((1-(*tert*-Butoxycarbonyl)piperidin-4-yl)oxy)benzo\[*b*\]thiophene-2-carboxylic Acid **10** {#sec4.3}
----------------------------------------------------------------------------------------------

To a solution of **8** (2.50 g, 6.17 mmol) in MeOH (30 mL) was added LiOH·H~2~O (3.35 g, 79.8 mmol). The mixture was stirred at rt for 3 h. The mixture was concentrated under reduced pressure, dissolved in 100 mL water, and acidifed to pH 2 with 2 M HCl solution (30 mL). Precipitate was removed by filtration and washed with 5 × 10 mL of water, then dried in a vacuum desiccator, yielding **10** as an off-white solid (1.36 g, 58%). ^1^H NMR (CDCl~3~, δ, ppm) 7.87 (1H, d, *J* = 8.0), 7.81 (1H, d, *J* = 8.2), 7.53 (1H, ddd, *J* = 8.0, 7.0, 0.9), 7.44 (1H, dd, *J* = 8.2, 7.0), 4.82--4.73 (1H, m), 4.06--3.93 (2H, m), 3.15--3.03 (2H, m), 2.11--2.00 (2H, m), 1.94--1.80 (2H, m), 1.49 (9H, s).

*tert*-Butyl 4-((2-(((3-Methoxybenzyl)oxy)carbonyl)benzo\[*b*\]thiophen-3-yl)oxy)piperidine-1-carboxylate **11b** {#sec4.4}
-----------------------------------------------------------------------------------------------------------------

To a solution of **10** (50 mg, 0.13 mmol) in MeCN (2 mL) were added hydroxybenzotriazole (27 mg, 0.20 mmol), *N*,*N*-diisopropylethylamine (26 μL, 0.16 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (30 mg, 0.16 mmol). The mixture was stirred at rt for 15 min. (3-Methoxyphenyl)methanol (20 μL, 0.16 mmol) was added and the mixture stirred at rt for 18 h. The mixture was concentrated under reduced pressure and dissolved in 10 mL of saturated NH~4~Cl solution. **11b** was extracted with 3 × 10 mL EtOAc. Combined organic layers were washed with 10 mL of brine, dried over MgSO~4~, and concentrated under reduced pressure. The crude product was purified by flash chromatography, yielding **11b** as a colorless oil (37 mg, 60%). ^1^H NMR (CDCl~3~, δ, ppm) 7.86 (1H, d, *J* = 8.0), 7.75 (1H, d, *J* = 8.2), 7.51--7.46 (1H, m), 7.43--7.37 (1H, m), 7.32 (1H, apparent t, *J* = 7.9), 7.04 (1H, d, *J* = 7.8), 7.02--7.00 (1H, m), 6.90 (1H, dd, *J* = 8.2, 2.3), 5.35 (2H, s), 4.74--4.66 (1H, m), 3.94--3.86 (2H, m), 3.84 (3H, s), 3.07--2.98 (2H, m), 1.98--1.88 (2H, m), 1.85--1.73 (2H, m), 1.48 (9H, s).

3-Methoxybenzyl-3-(piperidin-4-yloxy)benzo\[*b*\]thiophene-2-carboxylate **12b** {#sec4.5}
--------------------------------------------------------------------------------

To a solution of **11b** (34 mg, 0.07 mmol) in DCM (1.00 mL) was added TFA (100 μL). The solution was stirred at rt for 2 h. The mixture was concentrated under reduced pressure and purified by HPLC, yielding **12b** as a colorless oil (5 mg, 18%). *t*~R~ = 12.3 min; ^1^H NMR (CDCl~3~, δ, ppm) 7.82 (1H, d, *J* = 8.0), 7.76 (1H, d, *J* = 8.1), 7.56--7.48 (1H, m), 7.47--7.40 (1H, m), 7.33 (1H, apparent t, *J* = 7.9), 7.04 (1H, d, *J* = 7.4), 7.01--6.98 (1H, m), 6.91 (1H, dd, *J* = 8.2, 2.4), 5.34 (2H, s), 4.88--4.81 (1H, m), 3.84 (3H, s), 3.54--3.44 (2H, m), 3.11--3.01 (2H, m), 2.22--2.11 (4H, m). ^13^C NMR (CDCl~3~, δ, ppm) 161.48, 159.84, 153.90, 138.23, 136.98, 134.06, 129.82, 128.39, 125.07, 123.14, 122.61, 120.34, 115.87, 113.81, 113.79, 76.10, 66.82, 55.29, 41.01, 28.07. ESI HRMS, found 398.1425 (C~22~H~24~NO~4~S, \[M + H\]^+^, requires 398.1426).

Experimental procedure, characterization of intermediates and target compounds, description of biological assays, determination of *K*~i~ values, biological data of supplementary compounds, and crystallographic information. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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nd

:   not determined

Pf

:   *Plasmodium falciparum*

Pv

:   *Plasmodium vivax*

NMT

:   *N*-myristoyltransferase

Hs

:   *Homo sapiens*
